Table 36Characteristics of TZD interclass head-to-head trials in adults with type 2 diabetes

Author, year Country
Quality
Sample size (N)
Follow-up (weeks)
Age (years) (SD)a
% Femalea
% Whitea
% Hispanica
Other population characteristics
InterventionCombination therapy
DeFronzo, 201067
Fair
137
20
56 (10)
51
61
23
Rosiglitazone 8 mg daily

Exenatide 20 mcg daily

Exenatide and Rosiglitazone
Added to metformin
Marre 200984b
LEAD-1
Multinational
Fair
1040c
26
54.7–57.7 (9.0–10.0)
55
NR
NR
Inadequate glycemic control after >=3 month OGLAs
Rosiglitazone 4 mg daily

Liraglutide 0.6–1.8 mg daily
Added to glimepiride 2–4 mg daily
Rigby 201040
Fair
169
16
Rosi group:
54.7 (10.9)
58.9
28.6
67.9
Rosi 4 mg daily

Sitagliptin 100 mg daily

Colesevelam 3.75 g daily
Metformin 1500–2550 mg daily
Scott 200836
Multinational
Fair
273
18
55.2 (9.8)
45
61
NR
Inadequate glycemic control with metformin monotherapy
Rosiglitazone 8 mg daily

Sitagliptin 100 mg daily
Added to metformin ≥1500 mg daily

Abbreviations: mth, month(s); NR, not reported; OAD, oral antidiabetic drug; OGLA, oral glucose-lowering agent; SD, standard deviation; SE, standard error; TZD, thiazolidinedione.

a

Baseline data are from the comparator arms. Data shown are mean (SD) unless otherwise indicated.

b

Nauck 2009159 includes analyses of data from this trial.

c

1041 subjects were randomized; 1040 received at least 1 dose of medication and were included in data analysis.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.